Citation: Michael Kreuter,David J. Lederer,Maria Molina-Molina,Imre Noth,Claudia Valenzuela,Lutz Frankenstein,Derek Weycker,Mark Atwood,Klaus-Uwe Kirchgaessler,Vincent Cottin, (2019). Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis. CHEST, Volume 156, Issue 4, October 2019, Pages 706-714. https://www.sciencedirect.com/science/article/pii/S0012369219308827 Background Angiotensin peptides have been implicated in idiopathic pulmonary fibrosis (IPF) pathogenesis. Angiotensin modulators are used to treat arterial hypertension, a frequent comorbidity of IPF. […]
Category: Anti-fibrotic properties
Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosisand type 2 diabetes mellitus: a national claims‑based cohort analysis
Abstract BackgroundIdiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with high morbidity and limited treatment options. Type 2 diabetes mellitus (T2DM) is a common comorbid illness among patients with IPF and is often treated with metformin, the first-line agent in the management of T2DM. There is growing evidence demonstrating metformin’s anti-fibrotic properties; however, […]